James P. Brady, Ph.D. Director of Technical Applications MaxCyte

Expanding the Role of Transient Expression and Streamlining Migration to Stable Cell Line Generation

Scientists are faced with the task of producing candidates, such as bispecific antibodies, at increasing scale during biotherapeutic development, culminating in the generation of high-yield, stable cell lines for clinical-scale bioproduction. This task must be merged with company directives to accelerate timelines, reduce risk, and lower costs. 

Key factors to the success of fulfilling this mission include expressing candidates that produce biorelevant data, delaying generation of stable cell lines, and streamlining migration from transient to stable production.

MaxCyte offers an electroporation-based delivery platform that can transiently produce bispecifics and other antibody-like molecules in the cell line of choice while streamlining the generation of stable pools and clones.  Integration of this platform within production workflows ensures the expression of high-quality, functional bispecifics in the manufacturing cell background, expands the role of transient expression through gram-scale protein production, and improves the generation of high-yield stable cell lines.

Cell-Loading Technology

MaxCyte’s Flow Electroporation™ is a cell-loading technology for scalable, CHO-based production of high-titer bispecific antibodies. Numerous data, both internally and customer-generated, have illustrated the production of quality, biologically active bispecific antibodies and Fc fragments.

Experiments in Dr. Matthias Peipp’s laboratory (Christian-Albrechts-University) resulted in the expression of high-quality, bispecific tandem scFvs (bispecific T cell engaging (BiTE)-like format) targeting CD19 x CD3 and Her2 x CD3 as well as bispecific tribodies targeting Her2 x CD16.  Importantly, the purified bispecifics exhibited specific target cell and effector cell binding, and facilitated T-cell mediated lysis of tumor cells in functional assays.

MaxCyte’s high levels of CHO transfection efficiency and cell viability that are critical for increasing transient productivity can also significantly reduce the time needed for cell recovery during selection, create stable pools enriched for high producers, and shorten the timeline of clonal cell-line generation. 

James Brady, Ph.D. ([email protected]), is vice president, technical applications and customer support at MaxCyte.

Previous articleTeam Describes Novel High-Throughput Cancer Screening System
Next articleQuantifying Stability for Biologics